PLCXD1

Across TCGA pan-cancer cohorts, PLCXD1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PLCXD1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PLCXD1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLCXD1 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRC, LIHC, and THCA are the cancer types where PLCXD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLCXD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	III,IV	+0.476	<.001	10	view →
LIHC	Female	All	+1.386	<.001	7	view →
THCA	All	All	−0.419	<.001	7	view →
KICH	Female	II,III,IV	−0.981	<.001	5	view →
UCEC	All	All	+0.641	.027	2	view →
LUAD	All	All	−0.342	.025	2	view →
PRAD	All	All	+0.272	.017	2	view →
LUSC	Male	III,IV	+1.065	.003	1	view →
CHOL	All	All	+0.974	.017	1	view →
COAD	Female	All	+0.462	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PLCXD1–KIRC

Open the KIRC breakdown →